HTG Launches HTG EdgeSeq Reveal
Summary
HTG’s new software, when coupled with the HTG EdgeSeq Precision Immuno-Oncology panel, enables applications such as the immunophenotyping of tumor infiltrating lymphocytes (TILs); monitoring of immunotherapy response biomarkers; and the elucidation of immune-escape mechanisms known to drive disease progression. Using only a single 5 µm formalin-fixed, paraffin-embedded (FFPE) tissue section, the panel profiles 1,392 genes, without the RNA extraction and complex workflow associated with standard RNA-seq methods. Together with the HTG EdgeSeq system, customers using the new HTG EdgeSeq Reveal software will have the ability to conduct molecular profiling using a wide variety of sample types, potentially enabling them to accelerate discovery, support translational applications, and determine potential biomarkers for development of companion diagnostics. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect.